Evidence map›Paper›PMID 29243205›Full record

ArticleTargeted oncology2018

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

Maria Alsina, Fernando Rivera, Francisco Javier Ramos, Maica Galán, Rafael López, Pilar García-Alfonso, José Enrique Alés-Martinez, Bernardo Queralt, Antonio Antón, Alfredo Carrato and 8 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Maria AlsinaVall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain. malsina@vhio.net.ORCID 0000-0003-4835-7159
Fernando RiveraDepartment of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain.
Francisco Javier RamosVall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
Maica GalánDepartment of Medical Oncology, ICO Hospitalet, Avinguda de la Granvia, 199-203, Barcelona, Spain.
Rafael LópezMedical Oncology Department and Translational Medical Oncology Group, University Clinical Hospital and Health Research Institute (IDIS); CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain.
Pilar García-AlfonsoDepartment of Medical Oncology, H. Gregorio Marañón, Calle del Dr. Esquerdo, 46, Madrid, Spain.
José Enrique Alés-MartinezDepartment of Medical Oncology, H. Ruber Internacional, Calle de la Masó, 38, Madrid, Spain.
Bernardo QueraltDepartment of Medical Oncology, H. JosepTrueta (ICO), Avinguda de França, Girona, Spain.
Antonio AntónDepartment of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, Zaragoza, Spain.
Alfredo CarratoDepartment of Medical Oncology, H. Ramón y Cajal, Ctra. Colmenar Viejo, km. 9, 100 Madrid, Spain.
Cristina GrávalosDepartment of Medical Oncology, H. 12 de Octubre, Avenida de Córdoba, Madrid, Spain.
Maria José Méndez-VidalMaimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, Department of Medical Oncology, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Av. Menendez Pida, Cordoba, Spain.
Carlos LópezDepartment of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain.
Inmaculada Ruiz de MenaTTD Group, Madrid, Spain.
Josep TaberneroVall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
Jordi GiraltDepartment of Radiation Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
Enrique ArandaMaimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, Department of Medical Oncology, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Av. Menendez Pida, Cordoba, Spain.
Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Errors were subsequently identified in the article and the following corrections should be noted.

Identifiers

PMID29243205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.